OABI

OmniAb, Inc. (OABI) - Q3 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2024. OmniAb, Inc. is a biotechnology company that licenses discovery research technology to pharmaceutical and biotech industries. The company utilizes a proprietary platform called "Biological Intelligence" to create optimized antibody candidates. As of September 30, 2024, the company had 86 active partners and 352 active programs, including 29 antibodies in clinical development and three approved products.

Key Financial Metrics

Note: Cash and short-term investments combined total $59.38 million as of September 30, 2024 ($27.24 million cash + $32.15 million short-term investments).

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 24% in Q3 2024 compared to Q3 2023 and 47% on a year-to-date basis. The YTD decline was primarily driven by a $10 million milestone recognized in the prior year related to the first commercial sale of TECVAYLI in the EU and $2.5 million in milestones for batoclimab pivotal studies.
• Expense Management: Operating expenses decreased 7% in Q3 2024 and 4% YTD. General and administrative expenses dropped 17% in Q3 due to lower legal and share-based compensation costs. Research and development expenses remained relatively flat YTD.
• Contingent Liabilities: The company recorded a $2.4 million reduction in contingent liabilities (recognized as income) in the nine months ended September 30, 2024, attributed to changes in ion channel programs.
• Intangible Asset Impairment: A $1.2 million impairment was recorded on finite-lived intangible assets related to legacy assets from the 2019 acquisition of Ab Initio.

Outlook, Risks, and Management Commentary

• Liquidity: Management believes existing cash, cash equivalents, and short-term investments ($59.4 million) are sufficient to support operations for at least the next 12 months. The company continues to incur losses as it invests in R&D and platform expansion.
• Capital Raising: The company maintains an "At-The-Market" (ATM) facility with Jefferies LLC for up to $100 million. During the nine months ended September 30, 2024, the company issued shares for net proceeds of $8.5 million under this facility.
• Warrants: The company has outstanding public and private warrants with an exercise price of $11.50. As of the report date, these warrants are "out of the money," and the company does not expect cash proceeds from their exercise unless the stock price rises significantly.
• Risks: Key risks include the uncertainty of partner program progression, the timing of milestone and royalty payments, and the need for additional capital if cash flows are insufficient. The company is an Emerging Growth Company and a Smaller Reporting Company.

Investor Verification Checklist

• Cash Runway: Verify the sustainability of the $59.4 million cash position against the current burn rate (approx. $35.8 million operating cash outflow YTD).
• Revenue Concentration: Assess the impact of the absence of large, one-time milestone payments (like the $10M TECVAYLI milestone) on future revenue guidance.
• Partner Pipeline: Monitor the progression of the 29 clinical programs and 3 approved products to gauge future royalty potential.
• ATM Utilization: Track the remaining capacity under the $100 million ATM facility and the frequency of share issuances.
• Warrant Redemption: Monitor the stock price relative to the $11.50 warrant exercise price to assess potential future dilution or cash inflow.